Clinicopathologic features and treatment efficacy of patients with BRAF V600E-mutated metastatic colorectal cancer: a multi-center real-world propensity score matching study
The overall prognosis of BRAF V600E mutant mCRC patients is poor. Poor differentiation and liver metastases were negative independent prognostic factors for OS. First-line triplet-drug therapy was associated with better OS, especially in patients with good physical condition and high tumor burden.
Authors
- Gui-Xia Wei
- Lin Xie (ORCID: https://orcid.org/0000-0002-8850-6764)
- Meng Qiu (ORCID: https://orcid.org/0000-0003-3722-6938)
- Peng Cao (ORCID: https://orcid.org/0000-0002-6105-8543)
- Chao Dong (ORCID: https://orcid.org/0000-0002-0183-0087)
- Tao Zhang (ORCID: https://orcid.org/0000-0001-6643-4686)
- Yuwen Zhou
Institutions
- Chengdu Medical College (CN)
- Sichuan University (CN)
- Kunming Medical University (CN)
- West China Medical Center of Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1186/s12885-024-13171-z
- Citations
- 2
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Sichuan University
- West China Hospital, Sichuan University